瑞舒伐他汀对不稳定型心绞痛患者疗效及血清IL 6和hs CRP影响.docVIP

瑞舒伐他汀对不稳定型心绞痛患者疗效及血清IL 6和hs CRP影响 　　【摘要】 目的 观察瑞舒伐他汀治疗不稳定型心绞痛(UAP)的临床疗效及IL 6和hs CRP的变化。方法 选择98例UAP患者随机分为两组,对照组48例给予常规治疗;治疗组50例在对照组治疗的基础上加用瑞舒伐他汀口服。两组疗程均为8周。结果 治疗后治疗组心绞痛发作及心电图改善均显著优于对照组(P均0.05)。治疗组血清IL 6和hs CRP显著低于对照组(P0.05)。治疗组未见明显的不良反应。结论 瑞舒伐他汀治疗UAP能改善心绞痛症状及缺血心电图改变,显著降低血清IL 6和hs CRP的浓度,且无明显的不良反应。 　　【关键词】瑞舒伐他汀;不稳定型心绞痛;白细胞介素 6(IL 6);超敏C 反应蛋白(hs CRP) 　　 　　Effects of Rosuvastatin on serum IL 6 and hs CRP and on treatment of unstable angina pectoris 　　WEI Jing Xia,YANG Tao.Department of Cardiology,the First People’s Hospital of Xinxiang,Henan,Xinxiang 453000,China 　　【Abstract】 Objective To observe the clinical effect of Rosuvastatin in the treatment of unstable angina pectoris(UAP)and the clinical efficacy of IL 6 and hs CRP changes.Methods 98 cases of UAP patients were randomly divided into two groups.48 cases of control group were were given conventional treatment; 50 cases of treatment group given oral rosuvastatin based on the control group treatment.Both groups were treated for 8 weeks.Results After the treatment,the treatment group improvement of angina pectoris and ECG were significantly better than that of the control group(Pl0.05).In treatment group,serum IL 6 and hs CRP were significantly lower than those the control group(P0.05).Treatment group had no obvious adverse reactions.Conclusion Rosuvastatin treatment of UAP can improve symptoms of angina and ischemic ECG changes,have a significant reduction in serum IL 6 and hs CRP concentrations,and no significant adverse reactions. 　　【Key words】 Rosuvastatin; Unstable angina pectoris; Interleukin 6(IL 6); High sensitivity C reactive protein(hs CRP) 　　 　　不稳定型心绞痛(UAP)为不稳定的斑块破裂、炎症激活、血栓形成及血管内皮功能异常等引起,临床患者病情不稳定,极易发展为急性心肌梗死、甚至猝死。他汀类药物起初作为一种降低血胆固醇的药物被应用于UAP,但许多临床和基础试验证明这类药物还具有降脂以外的有益作用。它可以抑制冠脉内的炎症反应,稳定血管内斑块[1]。本研究拟通过观察瑞舒伐他汀对UAP患者疗效及血清IL 6和hs CRP的影响,来探讨瑞舒伐他汀对血管内皮功能及炎症反应的影响。 　　1 资料与方法 　　1.1 病例选择 选取2007年5月至2009年5月在本科住院的UAP患者98例,符合中华医学会心血管病学会制定的《不稳定性心绞痛诊断和治疗建议》中UAP诊断标准,并经心电图、心肌酶等检测确诊。心绞痛发作时伴有心电图相邻两个导联的ST段缺血性下降0.1 mv,T波倒置、低平。并